Ibogaine Treatment in Canada

Canada sits in an unusual category, and reading the regulator’s own reasoning is the fastest way to understand it.

Not a controlled substance

We checked the consolidated Controlled Drugs and Substances Act across all its schedules. Psilocybin, LSD and mescaline are present. Ibogaine, iboga and Tabernanthe appear nowhere.

Canada also has no general analogue provision with free-standing force, which is why the Prescription Drug List entry had to spell out derivatives explicitly. It reads: Ibogaine or its salts or derivatives or analogues.

Is ibogaine legal in Canada covers the legal position in detail.

What the listing does, in the regulator’s words

The notice announcing it is unusually candid about purpose:

Ibogaine is not authorized for use in Canada. Health Canada has received serious and fatal adverse reaction reports associated with the use of ibogaine. As a result, in June, 2015 Health Canada issued a risk communication to advise the public not to use ibogaine.

And on why listing helps:

The addition of ibogaine to the PDL would allow Health Canada to provide more effective risk-based oversight of ibogaine: by requiring sale only pursuant to a prescription, by restricting the compounding of products containing ibogaine, and by providing enforcement agents with increased authority to seize products which do not conform with the Canadian Food and Drugs Act and Regulations.

A precision on the date, because it is routinely conflated. The Prescription Drug List itself records an effective date of 16 May 2017. The notice announcing the addition is dated 19 May. Both are correct for different things.

What preceded it

In July 2015 Health Canada published an advisory about an unauthorised natural health product containing ibogaine, following a serious domestic adverse reaction report of abnormal heart rhythms.

The advisory named the products and the distributor, which is why we can: it warned about serious adverse reactions associated with ibogaine-containing products including death, respiratory arrest, cardiac problems such as irregular heartbeat, seizures, and symptoms related to psychiatric and metabolic dysfunction.

That is a regulator naming the cardiac risk two years before it acted on the scheduling, and it lines up with what the literature shows. Ibogaine and the heart covers the mechanism.

Can anyone be treated in Canada

Not as a service. There is no authorised ibogaine product, so there is nothing to prescribe in the ordinary way.

The route that exists in principle is the Special Access Programme, through which a practitioner may request an unauthorised drug for a specific patient with a serious condition where conventional therapies have failed, are unsuitable or are unavailable. It is granted per patient and per request, it depends on a manufacturer willing to supply, and it is not a standing permission.

We could not verify whether any such request for ibogaine has ever been granted; Canada publishes no register of them. And note that the eligibility criteria commonly quoted for that programme are the regulator’s administrative interpretation rather than regulation text, which is a distinction worth keeping if anyone quotes them at you.

What this means practically

Nobody in Canada can offer you ibogaine treatment lawfully as a service. What people do instead is travel, and finding treatment sets out what that means.

If a Canadian provider tells you the treatment is lawful here because ibogaine is not a controlled substance, they are describing half the law. The other half is the sentence the regulator wrote itself: it is not authorized for use in Canada.